Incidence Of Chemotherapy-Induced Neutropenia And Current Practice Of Prophylaxis With Granulocyte Colony-Stimulating Factors In Cancer Patients In Spain: A prospective, observational study

European Journal of Cancer Care

Volumn 22, Issue 4, 2013, Pages 513-521

  Jolis, L ^a   Carabantes, F ^b   Pernas, S ^c   Cantos, B ^d   Lopez A ^e   Torres, P ^f   Funes, C ^g   Caballero, D ^h   Benedit, P ⁱ   Salar, A ^j  

^a HOSPITAL GENERAL DE GRANOLLERS   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f HOSPITAL JUAN CANALEJO   (Spain)

^g Allergy Section   (Spain)

^h HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

ⁱ SA   (Spain)

^j HOSPITAL DEL MAR   (Spain)

more..

Author keywords

Granulocyte colony stimulating factors; Multi cycle chemotherapy; Neutropenia

Indexed keywords

EID: 84879500671     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/ecc.12057     Document Type: Article

References (30)

1. Aapro M.S., Cameron D.A., Pettengell R., Bohlius J., Crawford J., Ellis M., Kearney N., Lyman G.H., Tjan-Heijnen V.C., Walewski J., Weber D.C. & Zielinski C. (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. European Journal of Cancer 42, 2433-2453.
2. Balducci L., Al-Halawani H., Charu V., Tam J., Shahin S., Dreiling L. & Ershler W.B. (2007) Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. The Oncologist 12, 1416-1424.
3. Cooper K.L., Madan J., Whyte S., Stevenson M.D. & Akehurst R.L. (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 11, 404.
4. Crawford J., Ozer H., Stoller R., Johnson D., Lyman G., Tabbara I., Kris M., Grous J., Picozzi V., Rausch G., Smith R., Gradishar W., Yahanda A., Vincent M., Stewart M. & Glaspy J. (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. The New England Journal of Medicine 325, 164-170.
5. Crawford J., Althaus B., Armitage J., Blayney D.W., Cataland S., Dale D.C., Demetri G.D., Foran J., Heaney M.L., Htoy S., Kloth D.D., Lyman G.H., Michaud L., Motl S., Vadhan-Raj S., Wong M.K. & National Comprehensive Cancer Network (2005) Myeloid growth factors clinical practice guidelines in oncology. Journal of National Comprehensive Cancer Network 3, 540-555.
6. Crawford J., Armitage J., Balducci L., Bennett C., Blayney D.W., Cataland S.R., Dale D.C., Demetri G.D., Erba H.P., Foran J., Freifeld A.G., Goemann M., Heaney M.L., Htoy S., Hudock S., Kloth D.D., Kuter D.J., Lyman G.H., Michaud L.B., Miyata S.C., Tallman M.S., Vadhan-Raj S., Westervelt P., Wong M.K. & National Comprehensive Cancer Network (2009) Myeloid growth factors. Journal of National Comprehensive Cancer Network 7, 64-83.
7. Del Giglio A., Eniu A., Ganea-Motan D., Topuzov E. & Lubenau H. (2008) XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. BMC Cancer 8, 332.
8. Doorduijn J.K., Van Der Holt B., Van Imhoff G.W., Van Der Hem K.G., Kramer M.H., Van Oers M.H., Ossenkoppele G.J., Schaafsma M.R., Verdonck L.F., Verhoef G.E., Steijaert M.M., Buijt I., Uyl-De Groot C.A., Van Agthoven M., Mulder A.H. & Sonneveld P. (2003) CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology 21, 3041-3050.
9. Eldar-Lissai A., Cosler L.E., Culakova E. & Lyman G.H. (2008) Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value in Health 11, 172-179.
10. Greil R., Psenak O. & Roila F. (2008) Hematopoietic growth factors: ESMO recommendations for the applications. Annals of Oncology 19 (Suppl. 2), ii116-ii118.
11. Grigg A., Solal-Celigny P., Hoskin P., Taylor K., McMillan A., Forstpointner R., Bacon P., Renwick J. & Hiddemann W. (2003) Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Leukemia and Lymphoma 44, 1503-1508.
12. Holmes F.A., Jones S.E., O'shaughnessy J., Vukelja S., George T., Savin M., Richards D., Glaspy J., Meza L., Cohen G., Dhami M., Budman D.R., Hackett J., Brassard M., Yang B.B. & Liang B.C. (2002) Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Annals of Oncology 13, 903-909.
13. Koumakis G., Vassilomanolakis M., Barbounis V., Hatzichristou E., Demiri S., Plataniotis G., Pamouktsoglou F. & Efremidis A.P. (1999) Optimal timing (preemptive versus supportive) of granulocyte colony-stimulating factor administration following high-dose cyclophosphamide. Oncology 56, 28-35.
14. Kuderer N.M., Dale D.C., Crawford J., Cosler L.E. & Lyman G.H. (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106, 2258-2266.
15. Lyman G.H. (2006) Risks and consequences of chemotherapy-induced neutropenia. Clinical Cornerstone 8 (Suppl. 5), S12-S18.
16. Lyman G.H., Kuderer N.M. & Djulbegovic B. (2002) Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. The American Journal of Medicine 112, 406-411.
17. Lyman G.H., Kuderer N., Agboola O. & Balducci L. (2003) Evidence-based use of colony-stimulating factors in elderly cancer patients. Cancer Control 10, 487-499.
18. Morrison V.A., Wong M., Hershman D., Campos L.T., Ding B. & Malin J. (2007) Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices. Journal of Managed Care Pharmacy 13, 337-348.
19. Osby E., Hagberg H., Kvaloy S., Teerenhovi L., Anderson H., Cavallin-Stahl E., Holte H., Myhre J., Pertovaara H. & Bjorkholm M. (2003) CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 101, 3840-3848.
20. Ozer H., Mirtsching B., Rader M., Luedke S., Noga S.J., Ding B. & Dreiling L. (2007) Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use. The Oncologist 12, 484-494.
21. Pettengell R., Schwenkglenks M., Leonard R., Bosly A., Paridaens R., Constenla M., Szucs T.D. & Jackisch C. (2008) Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Supportive Care in Cancer 16, 1299-1309.
22. Pinto L., Liu Z., Doan Q., Bernal M., Dubois R. & Lyman G. (2007) Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Current Medical Research and Opinion 23, 2283-2295.
23. Romieu G., Clemens M., Mahlberg R., Fargeot P., Constenla M., Schutte M., Easton V., Skacel T., Bacon P. & Brugger W. (2007) Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial. Critical Reviews in Oncology 64, 64-72.
24. Schippinger W., Holub R., Dandachi N., Bauernhofer T. & Samonigg H. (2006) Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim. Oncology 70, 290-293.
25. Shochat E. & Rom-Kedar V. (2008) Novel strategies for granulocyte colony-stimulating factor treatment of severe prolonged neutropenia suggested by mathematical modeling. Clinical Cancer Research 14, 6354-6363.
26. Viscoli C., Bruzzi P., Castagnola E., Boni L., Calandra T., Gaya H., Meunier F., Feld R., Zinner S., Klastersky J. & Glauser M. (1994) Factors associated with bacteraemia in febrile, granulocytopenic cancer patients. The International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). European Journal of Cancer 30A, 430-437.
27. Vogel C.L., Wojtukiewicz M.Z., Carroll R.R., Tjulandin S.A., Barajas-Figueroa L.J., Wiens B.L., Neumann T.A. & Schwartzberg L.S. (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. Journal of Clinical Oncology 23, 1178-1184.
28. Von Minckwitz G., Schwenkglenks M., Skacel T., Lyman G., Pousa A.L., Bacon P., Easton V. & Aapro M. (2009) Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis. European Journal of Cancer 45, 608-617.
29. Weycker D., Hackett J., Edelsberg J.S., Oster G. & Glass A.G. (2006) Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? The Annals of Pharmacotherapy 40, 402-407.
30. Wildiers H. & Reiser M. (2011) Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma. Critical Reviews in Oncology 77, 221-240.